Literature DB >> 20831478

Preclinical dynamic 18F-FDG PET - tumor characterization and radiotherapy response assessment by kinetic compartment analysis.

Kathrine Røe1, Thomas B Aleksandersen, Alexandr Kristian, Line B Nilsen, Therese Seierstad, Hong Qu, Anne H Ree, Dag R Olsen, Eirik Malinen.   

Abstract

BACKGROUND: Non-invasive visualization of tumor biological and molecular processes of importance to diagnosis and treatment response is likely to be critical in individualized cancer therapy. Since conventional static (18)F-FDG PET with calculation of the semi-quantitative parameter standardized uptake value (SUV) may be subject to many sources of variability, we here present an approach of quantifying the (18)F-FDG uptake by analytic two-tissue compartment modeling, extracting kinetic tumor parameters from dynamic (18)F-FDG PET. Further, we evaluate the potential of such parameters in radiotherapy response assessment.
MATERIAL AND METHODS: Male, athymic mice with prostate carcinoma xenografts were subjected to dynamic PET either untreated (n=8) or 24 h post-irradiation (7.5 Gy single dose, n=8). After 10 h of fasting, intravenous bolus injections of 10-15 MBq (18)F-FDG were administered and a 1 h dynamic PET scan was performed. 4D emission data were reconstructed using OSEM-MAP, before remote post-processing. Individual arterial input functions were extracted from the image series. Subsequently, tumor (18)F-FDG uptake was fitted voxel-by-voxel to a compartment model, producing kinetic parameter maps.
RESULTS: The kinetic model separated the (18)F-FDG uptake into free and bound tracer and quantified three parameters; forward tracer diffusion (k(1)), backward tracer diffusion (k(2)), and rate of (18)F-FDG phosphorylation, i.e. the glucose metabolism (k(3)). The fitted kinetic model gave a goodness of fit (r(2)) to the observed data ranging from 0.91 to 0.99, and produced parametrical images of all tumors included in the study. Untreated tumors showed homogeneous intra-group median values of all three parameters (k(1), k(2) and k(3)), whereas the parameters significantly increased in the tumors irradiated 24 h prior to (18)F-FDG PET.
CONCLUSIONS: This study demonstrates the feasibility of a two-tissue compartment kinetic analysis of dynamic (18)F-FDG PET images. If validated, extracted parametrical maps might contribute to tumor biological characterization and radiotherapy response assessment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20831478     DOI: 10.3109/0284186X.2010.498831

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  11 in total

1.  Influx rate of 18F-fluoroaminosuberic acid reflects cystine/glutamate antiporter expression in tumour xenografts.

Authors:  Kathinka E Pitman; Santosh R Alluri; Alexander Kristian; Eva-Katrine Aarnes; Heidi Lyng; Patrick J Riss; Eirik Malinen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-01       Impact factor: 9.236

Review 2.  Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future.

Authors:  Giampaolo Tomasi; Federico Turkheimer; Eric Aboagye
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

3.  Dynamic (18) F-FDG PET for Assessment of Tumor Physiology in Two Breast Carcinoma Xenografts.

Authors:  Alexandr Kristian; Line B Nilsen; Kathrine Røe; Mona-Elisabeth Revheim; Olav Engebråten; Gunhild M Mælandsmo; Ruth Holm; Eirik Malinen; Therese Seierstad
Journal:  Nucl Med Mol Imaging       Date:  2013-06-21

4.  2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363.

Authors:  Juliana Maynard; Sally-Ann Ricketts; Christelle Gendrin; Phillippa Dudley; Barry R Davies
Journal:  Mol Imaging Biol       Date:  2013-08       Impact factor: 3.488

5.  Dynamic 2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts.

Authors:  Alexandr Kristian; Jon Erik Holtedahl; Turid Torheim; Cecilia Futsaether; Eivor Hernes; Olav Engebraaten; Gunhild M Mælandsmo; Eirik Malinen
Journal:  Mol Imaging Biol       Date:  2017-04       Impact factor: 3.488

6.  Targeting presynaptic norepinephrine transporter in brown adipose tissue: a novel imaging approach and potential treatment for diabetes and obesity.

Authors:  M Reza Mirbolooki; Cristian C Constantinescu; Min-Liang Pan; Jogeshwar Mukherjee
Journal:  Synapse       Date:  2012-11-08       Impact factor: 2.562

7.  Radiation treatment monitoring using multimodal functional imaging: PET/CT ((18)F-Fluoromisonidazole & (18)F-Fluorocholine) and DCE-US.

Authors:  Natalia Arteaga-Marrero; Cecilie Brekke Rygh; Jose F Mainou-Gomez; Tom C H Adamsen; Nataliya Lutay; Rolf K Reed; Dag R Olsen
Journal:  J Transl Med       Date:  2015-12-18       Impact factor: 5.531

8.  Multimodality functional imaging in radiation therapy planning: relationships between dynamic contrast-enhanced MRI, diffusion-weighted MRI, and 18F-FDG PET.

Authors:  Moisés Mera Iglesias; David Aramburu Núñez; José Luis Del Olmo Claudio; Antonio López Medina; Iago Landesa-Vázquez; Francisco Salvador Gómez; Brandon Driscoll; Catherine Coolens; José L Alba Castro; Victor Muñoz
Journal:  Comput Math Methods Med       Date:  2015-02-19       Impact factor: 2.238

9.  G6Pase location in the endoplasmic reticulum: Implications on compartmental analysis of FDG uptake in cancer cells.

Authors:  Mara Scussolini; Matteo Bauckneht; Vanessa Cossu; Silvia Bruno; Anna Maria Orengo; Patrizia Piccioli; Selene Capitanio; Nikola Yosifov; Silvia Ravera; Silvia Morbelli; Michele Piana; Gianmario Sambuceti; Giacomo Caviglia; Cecilia Marini
Journal:  Sci Rep       Date:  2019-02-26       Impact factor: 4.379

10.  Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H.

Authors:  Mona-Elisabeth Revheim; Alexandr Kristian; Eirik Malinen; Øyvind Sverre Bruland; Jeanne-Marie Berner; Ruth Holm; Heikki Joensuu; Therese Seierstad
Journal:  Acta Oncol       Date:  2013-03-13       Impact factor: 4.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.